Category: 16506-27-7

T-cell lymphomas, version 2.2022 was written by Horwitz, Steven M.;Ansell, Stephen;Ai, Weiyun Z.;Barnes, Jeffrey;Barta, Stefan K.;Brammer, Jonathan;Clemens, Mark W.;Dogan, Ahmet;Foss, Francine;Ghione, Paola;Goodman, Aaron M.;Guitart, Joan;Halwani, Ahmad;Haverkos, Bradley M.;Hoppe, Richard T.;Jacobsen, Eric;Jagadeesh, Deepa;Jones, Allison;Kallam, Avyakta;Kim, Youn H.;Kumar, Kiran;Mehta-Shah, Neha;Olsen, Elise A.;Rajguru, Saurabh A.;Rozati, Sima;Said, Jonathan;Shaver, Aaron;Shea, Lauren;Shinohara, Michi M.;Sokol, Lubomir;Torres-Cabala, Carlos;Wilcox, Ryan;Wu, Peggy;Zain, Jasmine;Dwyer, Mary;Sundar, Hema. And the article was included in Journal of the National Comprehensive Cancer Network in 2022.Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase-pos., anaplastic large cell lymphoma, anaplastic lymphoma kinase-neg., and enteropathy-associated T-cell lymphoma. This discussion section focuses on the diagnosis and treatment of PTCLs as outlined in the NCCN Guidelines for T-Cell Lymphomas. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment was written by Bellesi, Silvia;Sali, Michela;Maiolo, Elena;Pereyra Boza, Maria del Carmen;Alma, Eleonora;Palucci, Ivana;Fatone, Federica;De Maio, Flavio;Viscovo, Marcello;D’Alo, Francesco;De Stefano, Valerio;Hohaus, Stefan;Sanguinetti, Maurizio. And the article was included in Leukemia & Lymphoma in 2022.Computed Properties of C16H21Cl2N3O2 The following contents are mentioned in the article:

Here, we show that patients vaccinated with the anti-SARS-CoV2 vaccine during active immunochemotherapy including the anti-CD20 Mab rarely (3.7%) show a Nab response, while the majority of patients vaccinated during cytotoxic therapy obtained a seroprotective. Response (80%). Still, Nab titers appeared to be lower in chemotherapy-treated patients with respect to a HC group. It is an open question whether routine control of Nab responses in these patients will be useful to estimate the individual level of protection against SARS-CoV2. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Computed Properties of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Computed Properties of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

SHINE a light: frontline ibrutinib for MCL was written by Killock, David. And the article was included in Nature Reviews Clinical Oncology in 2022.Reference of 16506-27-7 The following contents are mentioned in the article:

Many patients with mantle cell lymphoma (MCL) are ineligible for intensive therapy, including allogeneic stem cell transplantation (ASCT), and are instead treated with bendamustine and rituximab (BR). SHINE involved 523 patients aged �5 with stage II-IV MCL for whom ASCT was not planned. These results demonstrate the efficacy of combining ibrutinib with BR in patients with MCL. However, the optimal sequencing of these therapies, as well as other approved treatments, remains unclear. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Reference of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Treatment strategy for relapsed/refractory mantle cell lymphoma was written by Ishizawa, Kenichi. And the article was included in Ketsueki Naika in 2021.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

A review. According to Japanese data, the median age of onset is around 60 years, and the male-female ratio is 2:1 or higher, which is more common among males. This paper discusses treatment strategy for relapsed/refractory mantle cell lymphoma. Mantle cell lymphoma, its treatment options such as immunochemotherapy, mol.-targeted drug, and cell therapy were discussed. Also, discusses medical treatment effect after the first recurrence in young people, Treatment policy and future prospects. Currently, the combination therapy of various mol.-targeted drugs is being investigated, but the development is progressing with the ibrutinib and venetoclax combination therapy. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma was written by Vinti, Luciana;Pagliara, Daria;Buffardi, Salvatore;Di Ruscio, Valentina;Stocchi, Francesca;Mariggio, Elena;Parasole, Rosanna;Di Matteo, Antonia;Petruzziello, Fara;Paganelli, Valeria;De Vito, Rita;Del Bufalo, Francesca;Strocchio, Luisa;Locatelli, Franco. And the article was included in Pediatric Blood & Cancer in 2022.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Although children and young adults with Hodgkin’s lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90-120 mg/m² on days 2 and 3. At the end of treatment, the overall response rate was 81. The 3-yr overall and progression-free survivals are 78.1and 67, resp. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Case report: unremitting COVID-19 pneumonia, viral shedding, and failure to develop anti-SARS-CoV-2 antibodies for more than 6 months in patient with mantle cell lymphoma treated with rituximab was written by Berktas, Bahadir M.;Koyuncu, Adem. And the article was included in American Journal of Tropical Medicine and Hygiene in 2022.Related Products of 16506-27-7 The following contents are mentioned in the article:

Severe cases of COVID-19 are being reported in patients with comorbidities and drug-induced immunosuppression. The risk seems to depend on the type of immunosuppressive agents used, and it is particularly high with rituximab because of its long-lasting effects. We report a 71-yr-old man with COVID-19, mantle cell lymphoma, and rituximab-associated immunodeficiency. His COVID-19 clin. course was severe, unremitting, prolonged, and with frequent acute exacerbations requiring hospitalization. Viral shedding and failure to develop anti-severe acute respiratory syndrome coronavirus 2 antibodies continued for at least 6 mo. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Related Products of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Related Products of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy was written by Kamegai, Kohei;Iwamoto, Noriko;Togano, Tomiteru;Maeda, Kenji;Takamatsu, Yuki;Miyazato, Yusuke;Ishikane, Masahiro;Mizokami, Masashi;Sugiyama, Masaya;Iida, Shun;Miyamoto, Sho;Suzuki, Tadaki;Ohmagari, Norio. And the article was included in International Journal of Infectious Diseases in 2022.Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Although mRNA vaccines are substantially effective toward SARS-CoV-2 infection, patients with hematol. malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 Delta variant infection in a patient with mucosa-associated lymphoid tissue lymphoma with remission by bendamustine-rituximab (BR) therapy completed a year ago. The serol. study revealed impaired responsiveness toward vaccines and prolonged high viral load after infection. BR therapy seemingly induced an immune escape. Prevention and treatment strategies for such vulnerable patients should be clarified immediately. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Treatment of relapsed/refractory follicular lymphoma was written by Fukuhara, Noriko. And the article was included in Ketsueki Naika in 2021.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

A review. Follicular Iymphoma (FL) is a typical type of so-called indolent lymphoma that progresses on a yearly basis, accounting for about 20% of all B-cell lymphoma, and has increased in recent years in Japan as well as in Europe and the United States. In the normal recurrence group, there is no change in transformation, and most of the transformation is DLBCLNOS, but high grade Iymphoma with MYC locus is also observed in some cases. At that point, it will be necessary to further elucidate the pathophysiol. of follicular lymphoma with the new treatment opening 56 in order to judge the situation and select a better move. The addnl. effect of obinutuzumab on bendamustine therapy is verified in the case of rituximab resistance. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

In vitro, in vivo and in silico-driven identification of novel benzimidazole derivatives as anticancer and anti-inflammatory agents was written by Sathyanarayana, Reshma;Poojary, Boja;Srinivasa, Sudhanva M.;Merugumolu, Vijay K.;Chandrashekarappa, Revanasiddappa B.;Rangappa, Shobith. And the article was included in Journal of the Iranian Chemical Society in 2022.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

The synthesis of novel benzimidazole derivatives with varied carbon chain length was achieved via ′′one-pot′â€?nitro reductive cyclization (6a-o). In each case, compounds were determined by the elemental analyses, FT-IR, mass, ¹H and ¹³C NMR spectroscopy. Further, these derivatives were screened for their in vitro anticancer, in vitro and in vivo anti-inflammatory activities. The results revealed that the length of the carbon chain greatly affects the activity. Among the 15 derivatives, compound 6d induced maximum cell death in HeLa and A549 cell lines and compound 6a emerged as a potent anti-inflammatory agent. Also, the physicochem. properties of potent compounds were studied. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Indolent T cell lymphoma involving the central nervous system and successfully treated by bendamustine was written by Hui, Min;Chen, Miao. And the article was included in Annals of Hematology in 2022.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Peripheral T-cell lymphoma, not otherwise unspecified (PTCL-NOS), was most common among the peripheral T-cell lymphomas (PTCL) subtypes. The central nervous system (CNS) is rarely involved as the primary site, making it especially challenging for diagnosis and treatment. The present report describes a rare case of indolent PTCL involving the central nervous system, bone marrow, s.c. tissue, and muscles, which was successfully treated by the bifunctional alkylating agent bendamustine and allogeneic hematopoietic stem cell transplantation. This report describes the first known experience of patients with indolent T cell lymphoma involving the central nervous system treated with bendamustine. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem